Evaluation of Etest Method for Determining Fluconazole and Voriconazole MICs for 279 Clinical Isolates of Candida Species Infrequently Isolated from Blood
Open Access
- 1 March 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (3) , 1087-1090
- https://doi.org/10.1128/jcm.41.3.1087-1090.2003
Abstract
The performance of Etest in fluconazole and voriconazole testing of 279 isolates of uncommon Candida spp. was assessed in comparison with the National Committee for Clinical Laboratory Standards (NCCLS)-approved standard broth microdilution (BMD) method. The NCCLS method employed RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35°C. Etest MICs were determined with RPMI agar containing 2% glucose and were read after incubation for 48 h at 35°C. The isolates include Candida krusei , C. lusitaniae , C. guilliermondii , C. kefyr , C. rugosa , C. lipolytica , C. pelliculosa , C. dubliniensis , C. famata , C. zeylanoides , C. inconspicua , and C. norvegensis . Overall agreement between Etest and BMD MICs was 96% for fluconazole and 95% for voriconazole. Where a discrepancy was observed between Etest and the reference method, the Etest tended to give lower values with both fluconazole and voriconazole. The Etest method using RPMI agar appears to be a useful method for determining fluconazole and voriconazole susceptibilities of uncommon species of Candida .Keywords
This publication has 22 references indexed in Scilit:
- Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal SusceptibilityJournal of Clinical Microbiology, 2002
- Multicenter Comparative Evaluation of Six Commercial Systems and the National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida SpeciesJournal of Clinical Microbiology, 2002
- Precision and Accuracy of Fluconazole Susceptibility Testing by Broth Microdilution, Etest, and Disk Diffusion MethodsAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida sppAntimicrobial Agents and Chemotherapy, 2002
- Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of Candida SpeciesJournal of Clinical Microbiology, 2001
- Evaluation of Etest Method for Determining Posaconazole MICs for 314 Clinical Isolates of Candida SpeciesJournal of Clinical Microbiology, 2001
- International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance ProgramJournal of Clinical Microbiology, 2001
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- Fungemia and Colonization with Nystatin-Resistant Candida rugosa in a Burn UnitClinical Infectious Diseases, 1994